总循环游离DNA作为转移性结直肠癌一线奥沙利铂化疗前的预后生物标志物
该研究基于前瞻性多中心III期NORDIC-VII试验的回顾性事后分析,在493例转移性结直肠癌患者中定量血浆游离DNA(cfDNA),评估其在一线奥沙利铂化疗前的预后价值。cfDNA高于预设正常上限者中位总生存为16.6个月,低于上限者为25.9个月(HR=1.83,95%CI 1.51-2.21,P<0.001),多因素分析证实该结果。
要点
- cfDNA高于正常上限者中位总生存16.6个月,低于上限者25.9个月(HR=1.83,95%CI 1.51-2.21,P<0.001)。
- 多因素校正已确立的临床病理特征后,cfDNA的预后关联仍成立。
- cfDNA水平可由RECIST最长肿瘤直径总和、肝转移及白介素6反映的全身炎症反应预测。
核心结论
- cfDNA有望成为转移性结直肠癌一线奥沙利铂化疗前的微创且临床相关的预后生物标志物,并可能是与肿瘤负荷、肝转移和全身炎症反应相关的复杂实体。
研究设计与样本
- 基于前瞻性多中心III期NORDIC-VII试验的回顾性事后研究,从547份血浆样本中纯化DNA,用微滴数字PCR(B2M、PPIA)定量cfDNA并设淋巴细胞污染对照。
- cfDNA在493例患者中完成定量,54例被排除,主要因淋巴细胞污染。
- 主要临床终点为总生存。
主要发现
- B2M的cfDNA中位水平为7673等位基因/ml(1050-1645000),PPIA为5959等位基因/ml(555-854167)。
- cfDNA高于正常上限者中位总生存16.6个月,低于上限者25.9个月(HR=1.83,95%CI 1.51-2.21,P<0.001)。
- 多因素总生存分析校正已确立的临床病理特征后,该结果得到证实。
- 线性回归模型以RECIST最长肿瘤直径总和、肝转移存在及白介素6反映的全身炎症反应预测cfDNA水平(F(6, 357)=62.7,P<0.001)。
关键数值与推荐
- 预设正常上限来自假定健康个体队列,cfDNA高于该上限者中位总生存16.6个月,低于上限者25.9个月(HR=1.83,95%CI 1.51-2.21,P<0.001)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic colorectal cancer (mCRC) is a heterogeneous disease where prognosis is dependent both on tumor biology and host factors. Total circulating cell-free DNA (cfDNA) has shown to harbor prognostic information in mCRC, although less is known about the biological correlates of cfDNA levels in this patient group. The primary objective was to evaluate the prognostic value of pretreatment cfDNA in patients receiving the first-line oxaliplatin-based chemotherapy for mCRC, by using a predefined upper limit of normal (ULN) from a cohort of presumed healthy individuals. The secondary objective was to model cfDNA levels as a function of predefined tumor and host factors. PATIENTS AND METHODS: This was a retrospective post hoc study based on a prospective multicenter phase III trial, the NORDIC-VII study. DNA was purified from 547 plasma samples and cfDNA quantified by a droplet digital PCR assay (B2M, PPIA) with controls for lymphocyte contamination. Main clinical end point was overall survival (OS). RESULTS: cfDNA was quantified in 493 patients, 54 were excluded mainly due to lymphocyte contamination. Median cfDNA level was 7673 alleles/ml (1050-1 645 000) for B2M and 5959 alleles/ml (555-854 167) for PPIA. High cfDNA levels were associated with impaired outcome; median OS of 16.6 months for levels above ULN and 25.9 months for levels below ULN (hazard ratio = 1.83, 95% confidence interval 1.51-2.21, P < 0.001). The result was confirmed in multivariate OS analysis adjusting for established clinicopathological characteristics. A linear regression model predicted cfDNA levels from sum of longest tumor diameters by RECIST, the presence of liver metastases and systemic inflammatory response as measured by interleukin 6 (F(6, 357) = 62.7, P < 0.001). CONCLUSION: cfDNA holds promise as a minimally invasive and clinically relevant prognostic biomarker in mCRC before initiating first-line oxaliplatin-based chemotherapy and may be a complex entity associated with tumor burden, liver metastases and systemic inflammatory response. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00145314.
引用
- Hamfjord J, Guren TK, Dajani O, et al. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Ann Oncol. 2019. PMID: 31046124. doi:10.1093/annonc/mdz139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。